Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343658 | 0.79 | KEAP1 (0.42) | KMT2AMEN1KEAP1NFE2L2NPC1 | |
| SCHEMBL13342094 | 0.77 | TAS1R3 (0.52) | — | |
| SCHEMBL13212367 | 0.77 | TAS1R3 (0.52) | — | |
| SCHEMBL18425647 | 0.77 | KEAP1 (0.41) | KMT2AMEN1KEAP1NFE2L2NPC1 | |
| SCHEMBL18425646 | 0.77 | KEAP1 (0.41) | KMT2AMEN1KEAP1NFE2L2NPC1 | |
| SCHEMBL6867850 | 0.76 | KMT5B (0.60) | KMT2AMEN1NPC1HPGDALDH1A1 | |
| SCHEMBL27520450 | 0.74 | KMT2A (0.47) | KMT2AMEN1KEAP1NFE2L2GAA | |
| SCHEMBL353475 | 0.73 | — | — | |
| SCHEMBL2574566 | 0.73 | — | — | |
| SCHEMBL17926698 | 0.73 | KEAP1 (0.38) | KMT2AMEN1KEAP1NFE2L2UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006016237-A2 | HETEROCYCLIC DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-02-16 | — | — | WO | claimed |
| US-20250002487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CGAS, TDP1, CYP11B2 | KMT2A 4398/4885MEN1 69/4885KEAP1 2174/4885 |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | KMT2A 1642/4885MEN1 4274/4885KEAP1 2152/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | KMT2A 364/4885MEN1 3330/4885KEAP1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.